BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 28068084)

  • 1. Molecular Modeling Evaluation of the Enantiomers of a Novel Adenylyl Cyclase 2 Inhibitor.
    Rana N; Conley JM; Soto-Velasquez M; León F; Cutler SJ; Watts VJ; Lill MA
    J Chem Inf Model; 2017 Feb; 57(2):322-334. PubMed ID: 28068084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compounds.
    Brand CS; Hocker HJ; Gorfe AA; Cavasotto CN; Dessauer CW
    J Pharmacol Exp Ther; 2013 Nov; 347(2):265-75. PubMed ID: 24006339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric Inhibition of Adenylyl Cyclase Type 5 by G-Protein: A Molecular Dynamics Study.
    Frezza E; Amans TM; Martin J
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32957635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery, design and synthesis of potent agonists of adenylyl cyclase type 2 by virtual screening combining biological evaluation.
    Xu G; Yang Y; Yang Y; Song G; Li S; Zhang J; Yang W; Wang LL; Weng Z; Zuo Z
    Eur J Med Chem; 2020 Apr; 191():112115. PubMed ID: 32105982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A molecular dynamics study of adenylyl cyclase: The impact of ATP and G-protein binding.
    Frezza E; Martin J; Lavery R
    PLoS One; 2018; 13(4):e0196207. PubMed ID: 29694437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor.
    Conley JM; Brand CS; Bogard AS; Pratt EP; Xu R; Hockerman GH; Ostrom RS; Dessauer CW; Watts VJ
    J Pharmacol Exp Ther; 2013 Nov; 347(2):276-87. PubMed ID: 24008337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries.
    Jourdan KB; Mason NA; Long L; Philips PG; Wilkins MR; Morrell NW
    Am J Physiol Lung Cell Mol Physiol; 2001 Jun; 280(6):L1359-69. PubMed ID: 11350817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for inhibition of mammalian adenylyl cyclase by calcium.
    Mou TC; Masada N; Cooper DM; Sprang SR
    Biochemistry; 2009 Apr; 48(15):3387-97. PubMed ID: 19243146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of new Gβγ interaction sites in adenylyl cyclase 2.
    Boran AD; Chen Y; Iyengar R
    Cell Signal; 2011 Sep; 23(9):1489-95. PubMed ID: 21596131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian Nucleotidyl Cyclases and Their Nucleotide Binding Sites.
    Dove S
    Handb Exp Pharmacol; 2017; 238():49-66. PubMed ID: 27900607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gαi1 inhibition mechanism of ATP-bound adenylyl cyclase type 5.
    Narzi D; van Keulen SC; Röthlisberger U
    PLoS One; 2021; 16(1):e0245197. PubMed ID: 33493164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis for P-site inhibition of adenylyl cyclase.
    Tesmer JJ; Dessauer CW; Sunahara RK; Murray LD; Johnson RA; Gilman AG; Sprang SR
    Biochemistry; 2000 Nov; 39(47):14464-71. PubMed ID: 11087399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mechanism for adenylyl cyclase inhibition from the crystal structure of its complex with catechol estrogen.
    Steegborn C; Litvin TN; Hess KC; Capper AB; Taussig R; Buck J; Levin LR; Wu H
    J Biol Chem; 2005 Sep; 280(36):31754-9. PubMed ID: 16002394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate specificity determinants of class III nucleotidyl cyclases.
    Bharambe NG; Barathy DV; Syed W; Visweswariah SS; Colaςo M; Misquith S; Suguna K
    FEBS J; 2016 Oct; 283(20):3723-3738. PubMed ID: 27542992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of adenylyl cyclase-GαS interactions and identification of novel AC ligands.
    Jaggupilli A; Dhanaraj P; Pritchard A; Sorensen JL; Dakshinamurti S; Chelikani P
    Mol Cell Biochem; 2018 Sep; 446(1-2):63-72. PubMed ID: 29327289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based development of novel adenylyl cyclase inhibitors.
    Schlicker C; Rauch A; Hess KC; Kachholz B; Levin LR; Buck J; Steegborn C
    J Med Chem; 2008 Aug; 51(15):4456-64. PubMed ID: 18630896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Truncation and alanine-scanning mutants of type I adenylyl cyclase.
    Tang WJ; Stanzel M; Gilman AG
    Biochemistry; 1995 Nov; 34(44):14563-72. PubMed ID: 7578062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The A-kinase anchoring protein Yotiao binds and regulates adenylyl cyclase in brain.
    Piggott LA; Bauman AL; Scott JD; Dessauer CW
    Proc Natl Acad Sci U S A; 2008 Sep; 105(37):13835-40. PubMed ID: 18772391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs.
    Hu B; Nakata H; Gu C; De Beer T; Cooper DM
    J Biol Chem; 2002 Sep; 277(36):33139-47. PubMed ID: 12065575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a potent and selective adenylyl cyclase type 8 agonist by docking-based virtual screening.
    Weng Z; Xu G; Chen D; Yang Y; Song G; Shen W; Zhang S; Wang L; Yang W; Zuo Z
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126823. PubMed ID: 31776060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.